Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: A randomized, clinical trial

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 5, 2014, Pages 997-1004

  Hatamkhani, Shima ^a   Khalili, Hossein ^a   Karimzadeh, Iman ^a   Dashti Khavidaki, Simin ^a   Abdollahi, Alireza ^b   Jafari, Sirous ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti tuberculosis medication; Carnitine; Hepatotoxicity; Prevention

Indexed keywords

CARNITINE; ETHAMBUTOL; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; SOLUTION AND SOLUBILITY; TUBERCULOSTATIC AGENT;

ADULT; ANTITUBERCULOSIS DRUG INDUCED HEPATOTOXICITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DRUG-INDUCED LIVER INJURY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SOLUTION AND SOLUBILITY; STATISTICAL MODEL; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ALANINE TRANSAMINASE; ANTITUBERCULAR AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CARNITINE; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; SOLUTIONS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84898879193     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12474     Document Type: Article

References (57)

1. World Health Organization. Global Tuberculosis Report 2012. Geneva: World Health Organization, 2012.
2. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008; 23: 192-202.
3. Huang YS, Chern HD, Su WJ etal. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
4. Sharifzadeh M, Rasoulinejad M, Valipour F, Nouraie M, Vaziri S. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. Pharmacol. Res. 2005; 51: 353-358.
5. Sistanizad M, Azizi E, Khalili H, Hajiabdolbaghi M, Gholami K, Mahjub R. Antituberculosis drug-induced hepatotoxicity in Iranian tuberculosis patients: role of isoniazid metabolic polymorphism. Iran. J Pharm. Res. 2011; 10: 633-639.
6. Breen RA, Miller RF, Gorsuch T etal. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006; 61: 791-794.
7. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 1472-1477.
8. Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther. 2011; 89: 911-914.
9. Steele MA, Burk R, DesPrez R. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. CHEST J. 1991; 99: 465-471.
10. Thompson NP, Caplin ME, Hamilton MI etal. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur. Respir. J. 1995; 8: 1384-1388.
11. Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J. Clin. Exp. Hepatol. 2013; 3: 37-49.
12. Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol. Res. 2005; 31: 132-135.
13. Liu Q, Garner P, Wang Y, Huang B, Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 2008; 8: 365.
14. Swamy AH, Kulkarni RV, Koti BC, Gadad PC, Thippeswamy AH, Gore A. Hepatoprotective effect of Cissus quadrangularis stem extract against rifampicin-induced hepatotoxicity in rats. Indian J. Pharm. Sci. 2012; 74: 183-187.
15. Rana SV, Pal R, Vaiphei K, Singh K. Garlic hepatotoxicity: safe dose of garlic. Trop. Gastroenterol. 2006; 27: 26-30.
16. Pal R, Vaiphei K, Sikander A, Singh K, Rana SV. Effect of garlic on isoniazid and rifampicin-induced hepatic injury in rats. World J. Gastroenterol. 2006; 12: 636-639.
17. Santhosh S, Sini TK, Anandan R, Mathew PT. Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur. J. Pharmacol. 2007; 572: 69-73.
18. Saad EI, El-Gowilly SM, Sherhaa MO, Bistawroos AE. Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. Food Chem. Toxicol. 2010; 48: 1869-1875.
19. Ergul Y, Erkan T, Uzun H, Genc H, Altug T, Erginoz E. Effect of vitamin C on oxidative liver injury due to isoniazid in rats. Pediatr. Int. 2010; 52: 69-74.
20. Sukhanov DS. Effectiveness of the hepatoprotective activity of reamberine, remaxol, and ademethionine and risk assessment in their use in patients with respiratory tuberculosis and drug-induced liver injury. Ter. Arkh. 2012; 84: 26-29.
21. Gulcin I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006; 78: 803-811.
22. Jung J, Eo E, Ahn KO. A case of hemoperfusion and L-carnitine management in valproic acid overdose. Am. J. Emerg. Med. 2008; 26: 388 e3-3884.
23. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin. Toxicol. (Phila) 2009; 47: 101-111.
24. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr. Opin. Pediatr. 2007; 19: 206-210.
25. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur. Respir. J. 2005; 26: 462-464.
26. Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann. Pharmacother. 2010; 44: 1287-1293.
27. Hatamkhani S, Karimzadeh I, Elyasi S, Farsaie S, Khalili H. Carnitine and sepsis: a review of an old clinical dilemma. J. Pharm. Pharm. Sci. 2013; 16: 414-423.
28. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Seoul: World Medical Association, 2008.
29. American Thoracic Society Committee on Revision of Diagnostic Standards. Diagnostic standards and classification of tuberculosis in adults and children. US Department of Health and Human Services, Public Health Service, 2000.
30. Rafraf M, Karimi M, Rashid M, Jafari A. Effect of L-carnitine supplementation in comparison with moderate aerobic training on insulin resistance and anthropometric indices in obese women. ZUMS J. 2012; 20: 17-30.
31. Mandell GL, Bennett JE, Dolin R. Mycobacterium tuberculosis. In: Fitzgerald DW, ed. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. New York: Churchill Livingstone/Elsevier, 2010; 69-73.
32. Tostmann A, van den Boogaard J, Semvua H etal. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Trop. Med. Int. Health 2010; 15: 268-272.
33. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 1993; 46: 1323-1330.
34. Salamzadeh J, Rezaee H, Khalili H, Jafari S, Abdollahi A. Evaluation of serum level of carnitine in HIV-positive individuals and its possible explanatory factors. Future Virol. 2012; 7: 1021-1028.
35. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
36. Khalili H, Dashti-Khavidaki S, Rasoolinejad M, Rezaie L, Etminani M. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU J. Pharm. Sci. 2009; 17: 163-167.
37. Xia Y, Zhan S. Systematic review of anti-tuberculosis drug induced adverse reactions in China. Zhonghua jie he he hu xi za zhi=Zhonghua jiehe he huxi zazhi=Chin. J. Tuberc. Respir. Dis. 2007; 30: 419-423.
38. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev. 2004; 36: 301-312.
39. Puig T, Relat J, Marrero PF, Haro D, Brunet J, Colomer R. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res. 2008; 28: 3671-3676.
40. Saukkonen JJ, Cohn DL, Jasmer RM etal. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006; 174: 935-952.
41. Jirillo E, Altamura M, Munno I etal. Effects of acetyl-L-carnitine oral administration on lymphocyte antibacterial activity and TNF-alpha levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. Immunopharmacol. Immunotoxicol. 1991; 13: 135-146.
42. Jirillo E, Altamura M, Marcuccio C, Tortorella C, De Simone C, Antonaci S. Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration. Mediators Inflamm. 1993; 2: S17-20.
43. Fatouros IG, Douroudos I, Panagoutsos S etal. Effects of L-carnitine on oxidative stress responses in patients with renal disease. Med. Sci. Sports Exerc. 2010; 42: 1809-1818.
44. Miguel-Carrasco JL, Monserrat MT, Mate A, Vazquez CM. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur. J. Pharmacol. 2010; 632: 65-72.
45. Saluk-Juszczak J, Olas B, Wachowicz B, Glowacki R, Bald E. L-carnitine modulates blood platelet oxidative stress. Cell Biol. Toxicol. 2010; 26: 355-365.
46. Aoun B, Berard E, Vitkevic R, Dehee A, Bensman A, Ulinski T. L-carnitine supplementation and EPO requirement in children on chronic hemodialysis. Pediatr. Nephrol. 2010; 25: 557-560.
47. Mate A, Miguel-Carrasco JL, Monserrat MT, Vazquez CM. Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension. J. Physiol. Biochem. 2010; 66: 127-136.
48. Shaker ME, Houssen ME, Abo-Hashem EM, Ibrahim TM. Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress. J. Physiol. Biochem. 2009; 65: 225-233.
49. Dobrzynska I, Szachowicz-Petelska B, Skrzydlewska E, Figaszewski Z. Effect of L-carnitine on liver cell membranes in ethanol-intoxicated rats. Chem. Biol. Interact. 2010; 188: 44-51.
50. Ali SA, Faddah L, Abdel-Baky A, Bayoumi A. Protective effect of L-carnitine and coenzyme Q10 on CCl-induced liver injury in rats. Sci. Pharm. 2010; 78: 881-896.
51. Tunez I, Munoz MC, Medina FJ, Salcedo M, Feijoo M, Montilla P. Comparison of melatonin, vitamin E and L-carnitine in the treatment of neuro- and hepatotoxicity induced by thioacetamide. Cell Biochem. Funct. 2007; 25: 119-127.
52. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 2001; 299: 849-857.
53. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 2012; 29: 1-12.
54. Acetyl-L-carnitine. Monograph. Altern. Med. Rev. 2010; 15: 76-83.
55. El-Beshlawy A, Ragab L, Fattah AA etal. Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol. 2004; 111: 143-148.
56. Olszowy Z, Plewka A, Czech E etal. Effect of l-carnitine supplementation on xenobiotic-metabolizing hepatic enzymes exposed to methanol. Exp. Toxicol. Pathol. 2006; 57: 427-435.
57. Yamazaki H, Iketaki H, Shibata A, Nakajima M, Yokoi T. Activities of cytochrome P450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. Drug Metab. Pharmacokinet. 2002; 17: 47-53.